Aesica invests in high containment

Aesica is investing £3m in a new high containment facility at its Queensborough, UK, site. The facility, which is due to be completed by May 2011, will enable Aesica to manufacture potent drugs typically classed as Safebridge category 3 and significantly extend its current capabilities in the formulation and packaging of liquid and solid dosage forms. In addition, the new facility will also include security measures that will ensure it can manufacture Schedule II controlled drugs such as opiates.
The Northern Echo